The Next Wave in Weight Loss: Beyond GLP-1 with Triple Agonists and Novel Combinations
The landscape of obesity treatment is rapidly evolving, moving beyond traditional GLP-1 analogs towards more potent multi-receptor agonists and innovative combinations. Whereas drugs like semaglutide have already made a significant impact, the next generation of therapies promises even greater efficacy and potentially more nuanced effects on body composition.
Retatrutide: A Triple Threat in Obesity and Osteoarthritis
Eli Lilly’s retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, is generating considerable excitement. Phase 3 TRIUMPH-4 trial data revealed an average weight loss of 28.7% (71.2 lbs) at 68 weeks in participants with obesity and knee osteoarthritis. This represents the highest weight loss recorded in a Phase 3 obesity trial to date, surpassing even Lilly’s own tirzepatide.
The benefits extend beyond the scale. Retatrutide also demonstrated a substantial reduction in knee osteoarthritis pain – up to an average of 4.5 points (75.8%) on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) – and improvements in physical function. More than one in eight patients experienced complete relief from knee pain by the trial’s finish.
Survodutid: A Dual Agonist Showing Promise
Boehringer Ingelheim and Zealand Pharma are also making strides with survodutid, a dual agonist targeting GLP-1 and glucagon receptors. A Phase 2 study showed a weight loss of nearly 19% after 46 weeks. Like retatrutide and existing medications, survodutid is administered as a once-weekly injection.
Cagri/Sema: Combining Amylin Analogs with Semaglutide
Novo Nordisk is exploring a different approach with cagrilintid, an amylin analog, combined with semaglutide (Cagri/Sema). This combination, also administered weekly, aims to promote a more physiological weight loss, potentially preserving more muscle mass compared to GLP-1 mimetics alone. Phase 3 REDEFINE 1 trial data showed an average weight reduction of 23% after 68 weeks.
The rationale behind combining an amylin analog is to tap into a different pathway for appetite regulation and energy expenditure. Early data suggests this combination may offer a more sustainable approach to weight management.
The Rise of Multi-Receptor Agonists: Why They Function
The success of retatrutide and the potential of survodutid highlight the benefits of targeting multiple receptors involved in appetite and metabolism. GLP-1 analogs have been effective, but activating additional pathways – like GIP and glucagon – appears to amplify the effects, leading to greater weight loss and improvements in related health conditions.
Pro Tip: Consider discussing these emerging therapies with your healthcare provider to determine if they might be appropriate for your individual needs and health profile.
Seven More Trials on the Horizon
Eli Lilly has seven additional Phase 3 trials evaluating retatrutide in obesity and type 2 diabetes expected to complete in 2026. These trials will provide further insights into the drug’s efficacy, safety, and potential applications.
Frequently Asked Questions
Q: What is a triple agonist?
A: A triple agonist is a medication that activates three different hormone receptors – in the case of retatrutide, these are GIP, GLP-1, and glucagon receptors – to regulate appetite and metabolism.
Q: How often are these medications administered?
A: Retatrutide, survodutid, semaglutide, tirzepatide, and Cagri/Sema are all administered as once-weekly injections.
Q: Are there any side effects associated with these medications?
A: Dysesthesia, an abnormal sense of touch, has emerged as a potential side effect in the late-stage TRIUMPH-4 trial of retatrutide.
Q: What is WOMAC?
A: WOMAC stands for the Western Ontario and McMaster Universities Osteoarthritis Index. It’s a questionnaire used to assess pain, stiffness, and physical function in people with knee and hip osteoarthritis.
Did you realize? The TRIUMPH-4 trial included participants with a baseline BMI of ≥35 kg/m² in 84.0% of cases, representing a population with significant obesity.
Stay informed about the latest advancements in obesity treatment by subscribing to our newsletter and exploring our other articles on metabolic health.
Related reading